Evaluation of Amrubicin as a Third or Later Line of Chemotherapy for Advanced Non-Small Cell Lung Cancer

Publisher： Karger

E-ISSN： 1421-9794|59|2|99-105

ISSN： 0009-3157

Source： Chemotherapy, Vol.59, Iss.2, 2013-09, pp. : 99-105

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase I/II Study of Amrubicin and Nedaplatin in Patients with Untreated, Advanced, Non-Small Cell Lung Cancer

By  

Chemotherapy, Vol. 60, Iss. 3, 2015-03 ,pp. : 180-184

Karger

Access to resources Recommend Favorite

A Phase II Study of First-Line Chemotherapy with Weekly Carboplatin Plus Gemcitabine in Advanced Non-Small Cell Lung Cancer

By  

Chemotherapy, Vol. 58, Iss. 1, 2012-02 ,pp. : 78-83

Karger

Access to resources Recommend Favorite

Gefitinib Plus Interleukin-2 in Advanced Non-Small Cell Lung Cancer Patients Previously Treated with Chemotherapy

By Bersanelli Melissa   Buti Sebastiano   Camisa Roberta   Brighenti Matteo   Lazzarelli Silvia   Mazza Giancarlo   Passalacqua Rodolfo  

Cancers, Vol. 6, Iss. 4, 2014-09 ,pp. : 2035-2048

MDPI

Access to resources Recommend Favorite

The Value of Tumor Markers in Evaluating Chemotherapy Response and Prognosis in Chinese Patients with Advanced Non-Small Cell Lung Cancer

By  

Chemotherapy, Vol. 56, Iss. 6, 2010-11 ,pp. : 417-423

Karger

Access to resources Recommend Favorite

Reply to the Letter to the Editor by C. Nicolazzo et al.: “Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy”

By Alama Angela   Coco Simona   Vanni Irene   Grossi Francesco  

International Journal of Molecular Sciences, Vol. 18, Iss. 6, 2017-06 ,pp. : 1309-1309

MDPI

Access to resources Recommend Favorite